Population pharmacokinetics of vancomycin in elderly infectious patients

doi:10.12092/j.issn.1009-2501.2019.02.007

Abstract

Abstract:

AIM: To develop a population pharmacokinetic model of vancomycin in elderly infectious patients and evaluate the effect of individual factors on the pharmacokinetics of vancomycin. METHODS: A total of 130 steady state blood vancomycin concentration monitoring data were collected from 71 cases of elderly infectious patients. Phoenix NLME (Version 8.0) software was used to assess the influence of demographic characteristics on pharmacokinetic characters of vancomycin and establish the vancomycin population pharmacokinetics model in elderly patients. Then, verify the final model. RESULTS:One-compartment model was fitted to the vancomycin concentration data. The population value of V and CL were 33.44 L and 2.16 L/h, respectively. CL was found to be significantly related to the covariate of Ccr (P<0.01). CONCLUSION: The population pharmacokinetic model of vancomycin was established successfully in elderly infectious patients. The final model could be used to provide accurate individual pharmacokinetic parameters. CL was significantly influenced by the covariate of Ccr, which showed that it is better to administer drug according individual Ccr in clinical practice.

Key words: vancomycin, elderly infectious patients, population pharmacokinetics

CLC Number:

R969.1

ZHU Min, ZHANG Cuifeng, GUO Yiyun, ZHU Ziming. Population pharmacokinetics of vancomycin in elderly infectious patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 158-163.

References

［1］Levine DP. Vancomycin: a history［J］. Clin Infect Dis, 2006, 42 Suppl 1:S5-12.
［2］Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children［J］. Clin Infect Dis, 2011, 52(3):e18-55.
［3］Alvarez R, Lopez Cortes LE, Molina J, et al. Optimizing the clinical use of vancomycin［J］. Antimicrob Agents Chemother, 2016, 60(5):2601-2609.
［4］Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia［J］. Clin Ther, 2007, 29(6):1107-1115.
［5］Sakoulas G, Gold HS, Cohen RA, et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia［J］. J Antimicrob Chemother, 2006, 57(4):699-704.
［6］Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections［J］. Clin Pharmacokinet, 2004, 43(13):925-942.
［7］陈冰, 杨婉花, 张伟霞, 等.中国成年患者万古霉素群体药动学研究［J］. 药学与临床研究, 2013, 21(6):605-609.
［8］Boeckmann A, Sheiner L, Beal S. NONMEM Users Guide［M］. Part V: 102-103.
［9］张弨, 赵荣生, 翟所迪, 等.群体药代动力学概述［J］. 中国临床药理学杂志, 2013, 29(8):563-565.
［10］Deng C, Liu T, Zhou T, et al. Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis［J］. Int J Clin Pharmacol Ther, 2013, 51(5):407-415.
［11］Purwonugroho TA, Chulavatnatol S, Preechagoon Y, et al. Population pharmacokinetics of vancomycin in Thai patients［J］. Scientific World J, 2012, 2012:762649.
［12］Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients［J］. J Clin Pharm Ther, 2006, 31(5):447-454.
［13］Chung JY, Jin SJ, Yoon JH, et al. Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations［J］. J Korean Med Sci, 2013, 28(1):48-54.
［14］Lin WW, Wu W, Jiao Z, et al. Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens［J］. Eur J Clin Pharmacol, 2016, 72(1):29-37.
［15］Ji XW, Ji SM, He XR, et al. Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients［J］. Acta Pharmacol Sin, 2018, 39(2):286-293.
［16］Li X, Wu Y, Sun S, et al. Population Pharmacokinetics of Vancomycin in Postoperative Neurosurgical Patients and the Application in Dosing Recommendation［J］. J Pharm Sci, 2016, 105(11):3425-3431.
［17］翁芳娟. 万古霉素的群体药动学研究［J］. 海峡药学, 2013, 25(7):207-209.
［18］杨薇, 贺蓓, 邓晨辉. 下呼吸道感染重症患者万古霉素群体药代动力学研究［J］. 中华结核和呼吸杂志, 2017, 40(3):205-209.
［19］Moore JN, Healy JR, Thoma BN, et al. A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Therapy［J］. CPT Pharmacometrics Syst Pharmacol, 2016, 5(9):495-502.
［20］杨平, 刘亚欧, 时正媛, 等.万古霉素在重症监护患者的群体药代动力学模型建立与验证［J］. 中国临床药理学杂志, 2018，34(6)：656-659.

[1]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[2]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[3]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[4]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[5]	LIU Wei, XUE Junsheng, YU Zhiheng, WANG Ziyu, CHEN Rong, ZHOU Tianyan. Interpretation of pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer guidance for industry [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 86-94.
[6]	LIN Liangmo, FU Xiangjun, ZHONG Lili, WANG Hefang, WU Qiongshi, XIAO Jian. Establishment of population pharmacokinetics model of vancomycin in patients with Neutropenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1014-1022.
[7]	FU Xiangjun, HUANG Li, GUO Li, LIN Liangmo. Application of AUC/MIC as the therapeutic drug monitoring target of vancomycin in patients with severe infections of multi drug resistant gram positive bacteria [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 775-781.
[8]	XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi. Population pharmacokinetics of capecitabine in Chinese breast cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
[9]	LI Wenchao, BAI Xiangrong, LI Xiaoling, JIANG Dechun. Population pharmacokinetics/pharmacodynamics of tigecycline in the treatment of different infectious diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1265-1272.
[10]	GUO Xianzhong, LIN Rongfang, LIN Weiwei. Development of software for individualizing dosage regimens of vancomycin based on population pharmacokinetics models [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 30-39.
[11]	LI Jian, YANG Jinbo, WANG Yuzhu. Discussion on the format and content of new drug population pharmacokinetic study report [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 546-549.
[12]	XU Gaoqi, ZHANG Yiwen, ZHENG Xiaowei, LIU Yujia, LI Li, HUANG Ping. Missed and remedial dosage regimens of erlotinib by Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 540-545.
[13]	CHEN Wenjun, RUAN Zourong, XIANG Xiaoqiang. Development and application progress of physiologically based pharmacokinetic modeling and its combined use with other modeling methods [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 299-305.
[14]	LI Jian, YANG Jinbo, WANG Yuzhu. Applications of model-informed drug development (MIDD) on new drug research and development [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 1-8.
[15]	LIU Simin, CAI Jun, LI Huixin, YANG Li, ZHAO Yan, ZHANG Jinping. Research progress in population pharmacokinetics of voriconazole in adults [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1015-1023.